For example, the TRIBE study suggested that the combination of 5-Fluorouracil/oxaliplatin/irinotecan triplet (FOLFOXIRI) with bevacizumab could be beneficial for BRAF-mutated CRC, but subsequent meta-analyses did not confirm these findings, underscoring the need for more personalized treatment approaches. Here, BRAF is linked to colorectal carcinoma.